THE EFFECT OF THE 8-WEEK ATORVASTATIN TREATMENT ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME

Abstract

Objective.To study the effect of the 8-week treatment with atorvastatin on the quality of life (QOL) of hypertensive patients with metabolic syndrome.Design and methods.An 8-week open prospective study included 35 patients with essential hypertension (stage II), associated with metabolic syndrome. Along with the complete clinical, laboratory and instrumental examination, taken in a specialized cardiology clinic, MOS SF-36® questionnaire was used to study the QOL during atorvastatin treatment.Results and conclusions.The 8-week atorvastatin treatment (20 to 40 mg/day titrated individually) both contributes to statistically signifi cant reduction of atherogenic fractions of cholesterol and provides a positive dynamics of subjective evaluation of QOL by SF-36® scales in hypertensive patients with metabolic syndrome.